JP2020535180A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020535180A5 JP2020535180A5 JP2020517814A JP2020517814A JP2020535180A5 JP 2020535180 A5 JP2020535180 A5 JP 2020535180A5 JP 2020517814 A JP2020517814 A JP 2020517814A JP 2020517814 A JP2020517814 A JP 2020517814A JP 2020535180 A5 JP2020535180 A5 JP 2020535180A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- compound
- cancer
- heavy chain
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17194196 | 2017-09-29 | ||
| EP17194196.6 | 2017-09-29 | ||
| PCT/EP2018/076494 WO2019063802A1 (en) | 2017-09-29 | 2018-09-28 | ANTICANCER ANTI-IGF POLY THERAPY, ANTI PD-1 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020535180A JP2020535180A (ja) | 2020-12-03 |
| JP2020535180A5 true JP2020535180A5 (enExample) | 2021-11-11 |
Family
ID=60009481
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020517814A Pending JP2020535180A (ja) | 2017-09-29 | 2018-09-28 | 抗ｉｇｆ、抗ｐｆ−１の抗がん組み合わせ治療 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20200239559A1 (enExample) |
| EP (1) | EP3687573A1 (enExample) |
| JP (1) | JP2020535180A (enExample) |
| CN (1) | CN111148534A (enExample) |
| WO (1) | WO2019063802A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2019011945A (es) * | 2017-04-05 | 2019-11-28 | Boehringer Ingelheim Int | Terapia de combinacion contra cancer. |
| WO2021046634A1 (en) * | 2019-09-11 | 2021-03-18 | Boehringer Ingelheim Io Canada, Inc. | Methods of treating cancer by the use of pd-1 axis inhibitors and anti-periostin antibodies |
| CN112111575B (zh) * | 2020-09-22 | 2023-01-10 | 重庆医科大学附属第一医院 | 胰岛素样生长因子2在恶性肿瘤预后和治疗选择中的应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| PT2242773T (pt) | 2008-02-11 | 2017-09-15 | Cure Tech Ltd | Anticorpos monoclonais para o tratamento de tumores |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| UY32317A (es) | 2008-12-12 | 2010-07-30 | Boehringer Ingelheim Int | Anticuerpos anti-igf |
| US20130122005A1 (en) | 2011-10-27 | 2013-05-16 | Paul Adam | Anticancer combination therapy |
| US20140255413A1 (en) * | 2013-03-07 | 2014-09-11 | Boehringer Ingelheim International Gmbh | Combination therapy for neoplasia treatment |
| ES2755933T3 (es) * | 2014-01-24 | 2020-04-24 | Boehringer Ingelheim Int | Tratamiento contra el cáncer usando un antagonista del receptor del factor de crecimiento insulínico (IGF) en combinación con exemestano y everolimus |
| UA122479C2 (uk) * | 2014-01-24 | 2020-11-25 | Дана-Фарбер Кенсер Інстітьют, Інк. | Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1) |
| SG11201702401RA (en) | 2014-10-14 | 2017-04-27 | Novartis Ag | Antibody molecules to pd-l1 and uses thereof |
| EP3328418A1 (en) | 2015-07-29 | 2018-06-06 | Novartis AG | Combination therapies comprising antibody molecules to pd-1 |
| WO2017055291A1 (en) * | 2015-09-28 | 2017-04-06 | Boehringer Ingelheim International Gmbh | Anticancer combination therapy |
| US11725247B2 (en) * | 2016-02-29 | 2023-08-15 | Foundation Medicine, Inc. | Methods of treating cancer |
-
2018
- 2018-09-28 EP EP18773782.0A patent/EP3687573A1/en not_active Withdrawn
- 2018-09-28 US US16/649,763 patent/US20200239559A1/en not_active Abandoned
- 2018-09-28 WO PCT/EP2018/076494 patent/WO2019063802A1/en not_active Ceased
- 2018-09-28 JP JP2020517814A patent/JP2020535180A/ja active Pending
- 2018-09-28 CN CN201880063798.0A patent/CN111148534A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018146886A (ru) | Пути терапевтического применения ингибитора c-raf | |
| FI3548515T3 (fi) | Radioleimattuja anti-PD-L1-vasta-aineita immuno-PET-kuvantamiseen | |
| RU2019112029A (ru) | Применение комбинации антитела к pd-1 и ингибитора vegfr в изготовлении лекарственного средства для лечения злокачественных новообразований | |
| JP2020521797A5 (enExample) | ||
| JP2013520442A5 (enExample) | ||
| RU2017108173A (ru) | Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1 | |
| RU2019111722A (ru) | Антитела против siglec-15 и способы их применения | |
| RU2018123717A (ru) | Комбинированные лечения, их применения и способы | |
| JP2019536806A5 (enExample) | ||
| JP2017031160A5 (enExample) | ||
| RU2018105846A (ru) | Комбинация антагониста pd-1 с ингибитором egfr | |
| JP2022511394A5 (enExample) | ||
| JP2015532292A5 (enExample) | ||
| FI3845245T3 (fi) | Seerumin fosfaatin efektiivinen ja tehokas säätely optimaalista luunmuodostusta varten | |
| JP2013529183A5 (enExample) | ||
| JP2016502504A5 (enExample) | ||
| JP2016519650A5 (enExample) | ||
| JP2015514110A5 (enExample) | ||
| RU2017136709A (ru) | Комбинированное лечение немелкоклеточного рака легкого с выявленной мутацией в egfr | |
| RU2018123709A (ru) | Новые антитела для лечения онкологических заболеваний | |
| JP2022512851A5 (enExample) | ||
| JP2019512472A5 (enExample) | ||
| JP2019533682A5 (enExample) | ||
| RU2017134443A (ru) | Способ лечения с применением традипитанта | |
| JP2024533067A5 (enExample) |